mesowatch
HomeJudge Rejects Consolidation of Dow Mesothelioma Cases
divider

Judge Rejects Consolidation of Dow Mesothelioma Cases

judge rejects dow chemical

The case of Augustus Adams vs. the late Clarence Hales has been refused consolidation in a ruling issued by U.S. District Judge Richard E Myers II against Dow Chemical and Fluor, where he noted that the two cases were entirely different.

Adams and Hales were both employees of a DuPont plant in Kinston, North Carolina, where they worked from the 1950s through the 1980s, and apparently developed mesothelioma from exposure to asbestos.

Judge’s Rationale for Denying Consolidation

Judge Myers II pointed out that the two cases differed widely in occupation, exposure, and injury and decided that the differences between the two cases would likely cause prejudice and confusion if brought together.

Adams manned the insulation department and Hales the carpentry department, so there was a mix of exposure to various goods even though the departments were adjacent.

Moreover, the men were of different medical age and with different injuries, only Adams was still alive when the ruling was made.

Judge Myers II was quick to point out that the cases were difficult to show how distinct they were at trial in order to avoid a possible risk of prejudice and misunderstanding, and thus the court ruled against the case separation.

Arguments Against Consolidation

While Adams’ and Hales’ families pressed for consolidation based on the same allegations, witnesses and timeframes, Dow and Fluor claimed differences in occupational exposure and possible secondhand asbestos exposure for Hales.

The decision reflects the court’s acknowledgment that each case is very different and should be tried differently so that there is equal treatment.

Matthew Davis

Reading Time: 1 mins

Published On: May 19, 2023

Matthew Davis - author

Matthew Davis is a freelance journalist who has covered civil litigation for a variety of publications. He joined Mesowatch in 2016 and covers asbestos litigation developments in the U.S., as well as newsworthy asbestos cases.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer